Neurocrine Biosciences Inc (NASDAQ:NBIX)
| 96.55 Delayed Data As of 4:00pm ET |  -2.05 / -2.08%Today’s Change | 72.14 Today|||52-Week Range 136.26 | -10.18% Year-to-Date |
Latest NBIX News | Press Releases
No recent news for Neurocrine Biosciences Inc.
Today’s Trading
| Previous close | 98.60 |
| Today’s open | 98.00 |
| Day’s range | 96.52 - 99.36 |
| Volume | 20,389 |
| Average volume (3 months) | 890,475 |
| Market cap | $8.8B |
Data as of 4:00pm ET, 12/04/2020
Growth & Valuation
| Earnings growth (last year) | +72.61% |
| Earnings growth (this year) | +231.47% |
| Earnings growth (next 5 years) | +3.00% |
| Revenue growth (last year) | +74.65% |
| P/E ratio | 99.5 |
| Price/Sales | 13.06 |
| Price/Book | 13.64 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ZLABZai Lab Ltd | -0.10 | -0.09% |
| CRSPCRISPR Therapeutics ... | +6.78 | +4.83% |
| NVAXNovavax Inc | -2.78 | -2.15% |
| DNLIDenali Therapeutics ... | +6.36 | +9.59% |
Data as of 4:02pm ET, 12/04/2020
Financials
| Next reporting date | February 16, 2021 |
| EPS forecast (this quarter) | $0.68 |
| Annual revenue (last year) | $788.1M |
| Annual profit (last year) | $37.0M |
| Net profit margin | 4.70% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
